Sugi Predict

Sugi Predict / Compounds / SCHEMBL59641

SCHEMBL59641

SCHEMBL59641

CC(C)(C)OC(=O)N1CCOC(C(=O)O)C1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ PDK1 Q15118 2/20 0.53
▸ RECQL P46063 1/20 0.48
▸ MAPT P10636 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ HPGD P15428 1/20 0.43
▸ EPHX1 P07099 1/20 0.41
▸ NR1H2 P55055 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ USP30 Q70CQ3 2/20 0.40
▸ GPR119 Q8TDV5 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL194709 1.00 USP2 (0.54) USP2SMN1; SMN2PDK1RECQLMAPT
SCHEMBL194710 1.00 USP2 (0.54) USP2SMN1; SMN2PDK1RECQLMAPT
SCHEMBL30538011 0.91 MAPT (0.53) USP2SMN1; SMN2PDK1RECQLMAPT
SCHEMBL16932340 0.91 MAPT (0.53) USP2SMN1; SMN2PDK1RECQLMAPT
SCHEMBL16932282 0.91 MAPT (0.53) USP2SMN1; SMN2PDK1RECQLMAPT
SCHEMBL30987122 0.90 MAPT (0.52) USP2SMN1; SMN2PDK1RECQLMAPT
SCHEMBL13765388 0.88 USP2 (0.54) USP2SMN1; SMN2PDK1RECQLMAPT
SCHEMBL15655665 0.88 USP2 (0.54) USP2SMN1; SMN2PDK1RECQLMAPT
SCHEMBL17763193 0.86 RECQL (0.57) USP2SMN1; SMN2RECQLMAPTMEN1
SCHEMBL31126145 0.86 USP2 (0.53) USP2SMN1; SMN2PDK1RECQLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 957 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 — — WO claimed
WO-2026087442-A1 AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 — — WO disclosed
WO-2026088070-A1 COMPOUNDS PFIZER INC. (US) 2026-04-30 — — WO disclosed
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2026-04-23 — — US disclosed
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-04-02 — — US disclosed
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-02-12 — — US disclosed
US-20260022116-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) 2026-01-22 — — US disclosed
EP-4192833-B1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES RICHTER GEDEON NYRT (HU) 2026-01-21 — — EP disclosed
EP-4676476-A1 INHIBITORS OF TDP-43 AND TAU AGGREGATION Aquinnah Pharmaceuticals, Inc. (US) 2026-01-14 — — EP disclosed
US-12522618-B2 Copper complexes for treatment of neurodegenerative disorders ALS THERAPY DEVELOPMENT INSTITUTE (US) 2026-01-13 — — US disclosed
EP-1187810-A2 HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE SEPRACOR, INC. (US) 2002-03-20 — — EP disclosed
US-20020016337-A1 Heterocyclic analgesic compounds and methods of use thereof SEPRACOR INC. 2002-02-07 — — US disclosed
US-6335338-B1 Calcilytic compounds SMITHKLINE BEECHAM CORPORATION 2002-01-01 — — US disclosed
WO-2001092226-A1 HETEROCYCLIC ANALGESIC COMPOUNDS AND METHOD OF USE THEREOF SEPRACOR, INC. (US) 2001-12-06 — — WO disclosed
US-6291459-B1 Calcilytic compounds SMITHKLINE BEECHAM CORPORATION 2001-09-18 — — US disclosed
EP-1112073-A1 CALCILYTIC COMPOUNDS SmithKline Beecham Corporation (US) 2001-07-04 — — EP disclosed
EP-1104411-A1 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-06 — — EP disclosed
WO-2000071518-A2 HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE SEPRACOR, INC. (US) 2000-11-30 — — WO disclosed
WO-2000009132-A1 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2000-02-24 — — WO disclosed
WO-2000009491-A1 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2000-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE IL6ST, GFRA3, GFRA1 USP2 913/4885SMN1; SMN2 36/4885PDK1 1346/4885
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE GFRA3, IL6ST, GFRA1 USP2 906/4885SMN1; SMN2 37/4885PDK1 1368/4885
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS PARP2, PARP1, PARP11 USP2 2541/4885SMN1; SMN2 889/4885PDK1 899/4885
US-20020016337-A1 Heterocyclic analgesic compounds and methods of use thereof OPRL1, TRPV1, OPRK1 USP2 3980/4885SMN1; SMN2 3352/4885PDK1 2063/4885
US-20260022116-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF MAPK1, MAPK3, MAPK6 USP2 4661/4885SMN1; SMN2 3837/4885PDK1 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.